RxDoctor Payments Data

Ruth Freeman, MD

Internal Medicine · Bothell, WANPI 1073502829

Payments from drug & device makers

$1,238in general payments, 2019–2025

Across 65 payments — averaging $19.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$316
  • Jazz Pharmaceuticals Inc.$175
  • Novo Nordisk$136
  • Exact Sciences$104
  • Pfizer$99
  • Sanofi$85
  • plus $322 from 15 others

What the payments were for

  • Food & beverage$1,22699%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,238 in reported general payments places this provider in the 85th percentile of 2,038 internal medicine providers in Washington.

See all internal medicine providers in Washington

Medicare billing

Part B allowed, 2024
$37,268
Medicare patients
91
Services billed
284

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide72$128,671
OzempicSemaglutide50$57,442
EliquisApixaban11$15,664
TrulicityDulaglutide14$15,035
Estradiol41$5,873
MyrbetriqMirabegron11$4,984
Gabapentin68$3,469
Omeprazole53$1,375
Losartan Potassium146$1,368
Levothyroxine Sodium160$1,260
Liothyronine Sodium29$1,250
Hydroxychloroquine Sulfate15$1,035
Ropinirole Hcl21$1,025
Ipratropium Bromide33$911
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine11$910

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$316$143,70686 claims
Novo NordiskOzempic$136$57,44250 claims
PfizerEliquis$99$15,66411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,038 internal medicine providers in Washington.

Other internal medicine in Bothell

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →